

FORM 3

**UNITED STATES SECURITIES AND EXCHANGE
COMMISSION**

Washington, D.C. 20549

**INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF
SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL	
OMB Number:	3235-0104
Estimated average burden hours per response:	0.5

1. Name and Address of Reporting Person* <u>Kim Bobae</u> <hr/> (Last) (First) (Middle) <u>44 PROSPECT ST.</u> <u>APT. 536</u> <hr/> (Street) <u>MORRISTOWN NJ 07960</u> <hr/> (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) <u>03/30/2023</u>	3. Issuer Name and Ticker or Trading Symbol <u>Bellerophon Therapeutics, Inc. [BLPH]</u>	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) <u>VP Reg. Affairs & Quality</u>	5. If Amendment, Date of Original Filed (Month/Day/Year) <hr/> 6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	9,890	D	

**Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Restricted Stock Units	(1)	(2)	Common Stock	11,000	0	D	
Stock Options (right to buy)	(3)	09/30/2026	Common Stock	133	21	D	
Stock Options (right to buy)	(3)	12/07/2026	Common Stock	266	7.35	D	
Stock Options (right to buy)	(3)	03/22/2028	Common Stock	1,200	33	D	
Stock Options (right to buy)	(3)	01/02/2029	Common Stock	1,000	13.2	D	
Stock Options (right to buy)	(4)	09/26/2029	Common Stock	1,166	7.5	D	
Stock Options (right to buy)	(5)	02/10/2033	Common Stock	50,000	1.52	D	

Explanation of Responses:

- Each restricted stock unit represents the contingent right to receive, upon vesting of the unit, one share of Bellerophon common stock. The restricted stock units are scheduled to vest on December 8, 2023, as long as the reporting person remains in the service of Bellerophon through the respective vesting date.
- Not Applicable.
- Fully vested and exercisable.
- This option was granted on September 26, 2019. This option vests in quarterly installments over a four-years period from the date of grant.
- This option vests as to 25% of the underlying shares on February 10, 2024 and the remaining options vest quarterly over a period of 3 years thereafter.

/s/ Bobae Kim

04/03/2023

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.